Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

rt & ej mascull t/a medifab -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

rt & ej mascull t/a medifab -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

rt & ej mascull t/a medifab -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

rt & ej mascull t/a medifab -

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - diphtheria toxoid, adsorbed 2 [iu] (nlt, equiv to 2 lf per dose); pertactin 3ug; pertussis filamentous haemagglutinin 5ug; pertussis fimbriae 2+3 5ug; pertussis toxoid, adsorbed 2.5ug; polio virus type 1 29 dagu (mahoney, by parallel line method (equiv to 40 dagu by sigmoid method)); polio virus type 2 7 dagu (mef 1, by parallel line method (equiv to 8 dagu by sigmoid method)); polio virus type 3 26 dagu (saukett, by parallel line method (equiv to 32 dagu by sigmoid method)); tetanus toxoid 20 [iu] (nlt, equiv to 5 lf per dose) - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 2 [iu] (nlt, equiv to 2 lf per dose) pertactin 3ug pertussis filamentous haemagglutinin 5ug pertussis fimbriae 2+3 5ug pertussis toxoid, adsorbed 2.5ug polio virus type 1 29 dagu (mahoney, by parallel line method (equiv to 40 dagu by sigmoid method)) polio virus type 2 7 dagu (mef 1, by parallel line method (equiv to 8 dagu by sigmoid method)) polio virus type 3 26 dagu (saukett, by parallel line method (equiv to 32 dagu by sigmoid method)) tetanus toxoid 20 [iu] (nlt, equiv to 5 lf per dose) excipient: aluminium phosphate ethanol phenoxyethanol polysorbate 80 water for injection - adacel® polio is indicated for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis in adults, adolescents and children aged 4 years and older as a booster following primary immunisation. children 4-6 years of age should have already received four doses of dtpa and ipv or opv. adacel® polio is not intended for primary immunisation. adacel® polio may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus. the use of adacel® polio should be determined on the basis of official recommendations.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)); polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)); polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) - suspension for injection - active: polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)) polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)) polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) excipient: formaldehyde phenoxyethanol polysorbate 80 water for injection - ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. recommendations for the use of live and inactivated poliovirus vaccines are described in the national immunisation guidelines. 1. general recommendations. it is recommended that all infants, unimmunised children and adolescents not previously immunised be vaccinated routinely against paralytic poliomyelitis. ipol should be offered to patients who have refused opv, or in whom opv is contraindicated. 2. ipol is also indicated for: · the primary vaccination of immunocompromised individuals of all ages (see precautions), and household contacts of such individuals (when vaccination is indicated) · unvaccinated or inadequately vaccinated (*) adults, particularly if at increased risk of exposure to live poliovirus, including: · travellers to areas or countries where poliomyelitis is epidemic or endemic; · laboratory workers handling specimens which may contain polioviruses; · health care workers in close contact with patients who may be excreting polioviruses. (*) such as those who had not completed a primary series of vaccination or not received a booster dose since infancy.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - 40768 - extracorporeal ultrasound imaging system transducer, hand-held - this extracorporeal ultrasound transducer assembly is a hand held device intended to be moved from location to location on the intact surface of a patient's body during imaging applications. it includes single or multiple element transducer assembly configurations that convert electric voltages into an ultrasound beam.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - 40772 - transducer assembly, ultrasound, diagnostic, intracorporeal, rectal - this transducer is intended for ultrasound imaging and is specifically designed to be positioned within the rectum either manually or under endoscopic guidance. it is intended to steer, focus, and detect the ultrasound beam and resulting echoes either mechanically or electronically. this device is reusable.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - 40771 - rectal/vaginal ultrasound imaging transducer - this transducer is intended for ultrasound imaging and is specifically designed to be positioned within the vagina either manually or under endoscopic guidance. it is intended to steer, focus, and detect the ultrasound beam and resulting echoes.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - 37891 - transducer assembly, ultrasound, diagnostic, intracorporeal, oesophageal - this transesophageal echocardiography endoscope is an invasive medical device entering through the oral cavity. normal use is either transient (inferior to 60 minutes per 93/42/eec) or short term (inferior to 30 minutes per 93/42/eec). it is not intended for long term use (superior to 30 days). this ultrasound probe is not surgically invasive. it is intended to be used on neonate (primary application), paediatric and adult patients for cardiology applications. it is intended to be used for: general assessment of the heart and valves function; cardiac valves assessment; assessment of valve lesions where trans thoracic cardiography may be inconclusive due to poor signal quality; assessment of interatrial septum, left ventricle, left atrial appendage.